莫努匹韦(molnupiravir) 是默克公司研发的口服抗新型冠状病毒肺炎新药, 是β-D-N4-
羟基胞苷(NHC) 的小分子核糖核苷前体药物, 其作用机制是干扰严重急性呼吸综合征冠状病毒2 …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

We thank Drs Kow, Ramachandram and Hasan for their interest in our review and their
knowledgeable comments. 1 We agree with your thoughtful view that the most important …

The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused numerous deaths
worldwide and poses significant challenges. Researchers have recently studied a new …

The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was
granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of …